Delandistrogene moxeparvovec

So rewind to the summer of last year.

Uh, we talked a lot about the major and very public saga that Sarepta faced over its Duchenne muscular dystrophy gene therapy, ELEVIDYS.

Multiple deaths were associated with the viral vector that underlies the treatment, led to two deaths in patients who had taken El-Elevidys and one who had taken an investigational gene therapy in a limb girdle muscular dystrophy trial.

And there-- it also-- the, the, uh, vector technology also underlay some of Sarepta's other pipeline candidates.

Such alliances are pivotal for enhancing access to affordable biologics, thereby improving healthcare affordability and accessibility.

Sarepta Therapeutics has been identified as a potential turnaround story with promising results from its Duchenne Muscular Dystrophy Gene Therapy, Elevides.

The therapy has shown clinically meaningful benefits, particularly for older ambulatory patients, suggesting a significant potential shift in the treatment landscape for DMD.

This development highlights the growing importance of gene therapy in addressing unmet medical needs and reflects the broader trend towards personalized medicine.

innovation, as also surging in metabolic and reproductive health.

Calera Therapeutics and Hangrui Pharma's GLP-1, GIP dual agonist demonstrated positive outcomes in trials for women with polyendocrine metabolic ovarian syndrome.